RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group
- 30 June 2004
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 40 (9) , 1332-1334
- https://doi.org/10.1016/j.ejca.2004.02.016
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Results of a 2‐arm Phase II study of 9‐nitrocamptothecin in patients with advanced soft‐tissue sarcomasCancer, 2003
- Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiformeEuropean Journal Of Cancer, 2002
- Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanomaAnti-Cancer Drugs, 2002
- Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer—significant effect of food intake on the bioavailability of the oral camptothecin analogueEuropean Journal Of Cancer, 2002
- A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinomaCancer Chemotherapy and Pharmacology, 2001
- Topotecan Versus Observation After Cisplatin Plus Etoposide in Extensive-Stage Small-Cell Lung Cancer: E7593—A Phase III Trial of the Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2001
- A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancerAnti-Cancer Drugs, 1999
- A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitorAnti-Cancer Drugs, 1998
- Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.Journal of Clinical Oncology, 1997
- CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.Journal of Clinical Oncology, 1992